New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

45

U.S. FDA Accepts BLA for Tislelizumab in ESCC

The U.S. Food and Drug Administration accepted for review a Biologics License Application (BLA) for the anti-PD-1 antibody tislelizumab as a treatment for patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic therapy.